Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.

Gabriele Gamerith,Finn Mildner,Peter A Merkel,Kristina Harris, Laura Cooney,Noha Lim,Robert Spiera,Philip Seo,Carol A Langford,Gary S Hoffman,E William St Clair,Fernando C Fervenza,Paul Monach,Steven R Ytterberg,Duvuru Geetha,Arno Amann,Dominik Wolf,Ulrich Specks,John H Stone,Andreas Kronbichler

Annals of the rheumatic diseases（2023）

引用 6|浏览39

暂无评分

摘要

Patients with AAV treated with rituximab achieved remission less frequently when concentrations of sLag-3 were low and concentrations of sCD27 were high. Higher concentrations of sTim-3, sCD27 and sBTLA at baseline predicted relapse in patients treated with rituximab. These results require confirmation but may contribute to a personalised treatment approach of AAV.

查看译文

关键词

autoimmune diseases,rituximab,systemic vasculitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要